Glenmark
-
{
- All
- News
- Videos
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
Stock Market Highlights: Markets End In Green As Wall Street, Asian Peers Edge Higher
Sensex Today | Nifty 50 | Stock Market Highlights: GIFT Nifty indicated another positive start for Nifty50 and the Sensex.
-
15 Lakh Bottles Of ADHD Medication Recalled In U.S. By Glenmark
ADHD is seen as a chronic and incapacitating disorder that affects a person's everyday functioning.
-
Cipla, Glenmark Recall Asthma Drugs Made In Indore From US Market
Drug makers Cipla and Glenmark are recalling products from the American market due to manufacturing issues, according to the US health regulator.
-
Glenmark Pharma To Sell 75% Stake In Life Sciences To Nirma For $680 Million
Drugmaker Glenmark Pharmaceuticals said on Thursday it would sell a 75% stake in unit Glenmark Life Sciences to detergent maker Nirma for 56.52 billion rupees ($679.84 million).
-
Glenmark Pharmaceuticals Recalls 1,200 Bottles Of "Subpotent" Hypertension Drug In US
Glenmark Pharmaceuticals is recalling 1,200 bottles of a generic drug, used to treat high blood pressure, in the American market due to a manufacturing issue, according to the US Food and Drug Administration (USFDA).
-
Glenmark Pharmaceuticals Gets Final US Approval For Lacosamide Tablet
Homegrown pharma major Glenmark Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic Lacosamide tablet, indicated for prevention and control of seizures.
-
5-Point Guide To The New Nasal Spray For Covid Cleared By India
A nasal spray to treat adult COVID-19 patients has been launched in India after Mumbai-based developers Glenmark Pharmaceuticals received marketing clearances from the Drugs Controller General of India as part of an accelerated approval process.
-
First Nasal Spray For Treating Adult Covid Patients Launched In India
Mumbai based innovation-driven global pharma company Glenmark has launched Nitric Oxide Nasal Spray (FabiSpray) in India, in partnership with SaNOtize, for treatment of adult patients suffering from COVID-19.
-
Central Drug Agency Seeks Clarification From Glenmark On Its COVID-19 Drug
The Drugs Controller General of India (DCGI) has asked for a clarification from Glenmark Pharmaceuticals regarding its alleged "false claims" on the utilisation of anti-viral FabiFlu (favipiravir) on COVID-19 patients with comorbidities.
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
Stock Market Highlights: Markets End In Green As Wall Street, Asian Peers Edge Higher
Sensex Today | Nifty 50 | Stock Market Highlights: GIFT Nifty indicated another positive start for Nifty50 and the Sensex.
-
15 Lakh Bottles Of ADHD Medication Recalled In U.S. By Glenmark
ADHD is seen as a chronic and incapacitating disorder that affects a person's everyday functioning.
-
Cipla, Glenmark Recall Asthma Drugs Made In Indore From US Market
Drug makers Cipla and Glenmark are recalling products from the American market due to manufacturing issues, according to the US health regulator.
-
Glenmark Pharma To Sell 75% Stake In Life Sciences To Nirma For $680 Million
Drugmaker Glenmark Pharmaceuticals said on Thursday it would sell a 75% stake in unit Glenmark Life Sciences to detergent maker Nirma for 56.52 billion rupees ($679.84 million).
-
Glenmark Pharmaceuticals Recalls 1,200 Bottles Of "Subpotent" Hypertension Drug In US
Glenmark Pharmaceuticals is recalling 1,200 bottles of a generic drug, used to treat high blood pressure, in the American market due to a manufacturing issue, according to the US Food and Drug Administration (USFDA).
-
Glenmark Pharmaceuticals Gets Final US Approval For Lacosamide Tablet
Homegrown pharma major Glenmark Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic Lacosamide tablet, indicated for prevention and control of seizures.
-
5-Point Guide To The New Nasal Spray For Covid Cleared By India
A nasal spray to treat adult COVID-19 patients has been launched in India after Mumbai-based developers Glenmark Pharmaceuticals received marketing clearances from the Drugs Controller General of India as part of an accelerated approval process.
-
First Nasal Spray For Treating Adult Covid Patients Launched In India
Mumbai based innovation-driven global pharma company Glenmark has launched Nitric Oxide Nasal Spray (FabiSpray) in India, in partnership with SaNOtize, for treatment of adult patients suffering from COVID-19.
-
Central Drug Agency Seeks Clarification From Glenmark On Its COVID-19 Drug
The Drugs Controller General of India (DCGI) has asked for a clarification from Glenmark Pharmaceuticals regarding its alleged "false claims" on the utilisation of anti-viral FabiFlu (favipiravir) on COVID-19 patients with comorbidities.
